Kazazian Asset Management LLC Invests $137,000 in MacroGenics, Inc. (NASDAQ:MGNX)

Kazazian Asset Management LLC bought a new position in shares of MacroGenics, Inc. (NASDAQ:MGNX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 42,036 shares of the biopharmaceutical company’s stock, valued at approximately $137,000.

Several other hedge funds have also modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. lifted its stake in MacroGenics by 12.5% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 744,902 shares of the biopharmaceutical company’s stock valued at $2,421,000 after buying an additional 82,988 shares in the last quarter. SPC Financial Inc. purchased a new position in MacroGenics in the 4th quarter valued at about $123,000. Charles Schwab Investment Management Inc. lifted its stake in MacroGenics by 7.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 527,185 shares of the biopharmaceutical company’s stock valued at $1,713,000 after buying an additional 34,420 shares in the last quarter. SG Americas Securities LLC lifted its stake in MacroGenics by 104.5% in the 4th quarter. SG Americas Securities LLC now owns 34,399 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 17,577 shares in the last quarter. Finally, XML Financial LLC lifted its stake in MacroGenics by 31.6% in the 4th quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 5,569 shares in the last quarter. 96.89% of the stock is owned by hedge funds and other institutional investors.

MacroGenics Trading Down 6.0 %

Shares of MacroGenics stock opened at $2.05 on Wednesday. The firm has a market capitalization of $128.66 million, a PE ratio of -1.30 and a beta of 2.12. MacroGenics, Inc. has a twelve month low of $2.04 and a twelve month high of $19.54. The firm’s 50-day moving average price is $2.73 and its 200 day moving average price is $3.24.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.